These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 2188784)

  • 1. Bone and joints alterations in uremic patients. Role of parathyroid hormone.
    Colussi G; De Ferrari ME; Rombolà G; Minola E; Benazzi E; Minetti L
    Contrib Nephrol; 1990; 77():157-67. PubMed ID: 2188784
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy of 19-Nor-1,25-(OH)2D2 in the prevention and treatment of hyperparathyroid bone disease in experimental uremia.
    Slatopolsky E; Cozzolino M; Lu Y; Finch J; Dusso A; Staniforth M; Wein Y; Webster J
    Kidney Int; 2003 Jun; 63(6):2020-7. PubMed ID: 12753289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of phosphorus in the genesis of azotemic osteodystrophy.
    Somerville PJ; Kaye M
    Prog Biochem Pharmacol; 1980; 17():228-35. PubMed ID: 6894195
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bone disease in uremic patients: advances in PTH suppression.
    Brancaccio D; Cozzolino M; Gorio A; Di Giulio AM; Gallieni M
    J Nephrol; 2002; 15 Suppl 6():S86-93. PubMed ID: 12515379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Calcium and phosphorus metabolism and bone disease in uremia.
    Kleeman CR; Massry SG; Coburn JW; Popovtzer MM
    Clin Orthop Relat Res; 1970; 68():210-37. PubMed ID: 4905786
    [No Abstract]   [Full Text] [Related]  

  • 6. [Uremic osteodystrophy. Critical evaluation of the radiologic and humoral indices of bone resorption].
    Galmozzi C; Casati S; Rivolta E; De Vecchi A; Imbasciati E; Cecchettin M; Brancaccio D; Ponticelli C
    Minerva Nefrol; 1979; 26(3):405-8. PubMed ID: 262283
    [No Abstract]   [Full Text] [Related]  

  • 7. Calciotropic hormones and the skeleton in uraemia.
    Lewin E; Olgaard K
    Eur J Clin Invest; 1999 Jun; 29(6):466-8. PubMed ID: 10354206
    [No Abstract]   [Full Text] [Related]  

  • 8. Effect of aluminium on the development of hyperparathyroidism and bone disease in the azotaemic rat.
    Felsenfeld AJ; Machado L; Bover J; Trinidad P; Rodriguez M
    Nephrol Dial Transplant; 1993; 8(4):325-34. PubMed ID: 8390007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bone disease in uremia.
    Stanbury SW
    Am J Med; 1968 May; 44(5):714-24. PubMed ID: 4869103
    [No Abstract]   [Full Text] [Related]  

  • 10. Famotidine reduces serum parathyroid hormone levels in uremic patients.
    Arik N; Arinsoy T; Sayín M; Taşdemir I; Yasavul U; Turgan C; Caglar S
    Nephron; 1991; 59(2):333. PubMed ID: 1956503
    [No Abstract]   [Full Text] [Related]  

  • 11. Quantitative histological studies on the pathogenesis of uremic bone disease.
    Sherrard DJ; Baylink DJ; Wergedal JE; Maloney NA
    J Clin Endocrinol Metab; 1974 Jul; 39(1):119-35. PubMed ID: 4835127
    [No Abstract]   [Full Text] [Related]  

  • 12. Beta-2-microglobulin amyloidosis and osteo-articular pathology of the uremic patient on regular dialysis.
    Brancaccio D; Anelli A; Gallieni M; Padovese P; Coggi G; Uslenghi C
    Contrib Nephrol; 1990; 77():177-86. PubMed ID: 2188786
    [No Abstract]   [Full Text] [Related]  

  • 13. [Periaticular metastatic calcifications in uremic patients].
    Fabbri L; Fusaroli M; Catizone L; Zucchelli P
    Minerva Med; 1975 Jan; 66(5):209-19. PubMed ID: 1113921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Parathyroid hormone and uremic neurotoxicity: an unproven association.
    Arieff AI; Armstrong DK
    Contrib Nephrol; 1980; 20():56-66. PubMed ID: 6995013
    [No Abstract]   [Full Text] [Related]  

  • 15. Search for the uremic toxin. Decreased motor-nerve conduction velocity and elevated parathyroid hormone in uremia.
    Avram MM; Feinfeld DA; Huatuco AH
    N Engl J Med; 1978 May; 298(18):1000-3. PubMed ID: 205786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Parathormone as a uremic toxin. Physiopathological bases and general therapeutic guidelines].
    Brancaccio D; Galmozzi C; Pizzocaro G
    Minerva Med; 1985 Mar; 76(9-10):377-82. PubMed ID: 3982693
    [No Abstract]   [Full Text] [Related]  

  • 17. The isolation and assay of human parathyroid hormone.
    O'Riordan JL; Woodhead JS
    Clin Sci; 1969 Oct; 37(2):572. PubMed ID: 5359029
    [No Abstract]   [Full Text] [Related]  

  • 18. Clinical review 20: Recent advances in the pathogenesis and therapy of uremic secondary hyperparathyroidism.
    Delmez JA; Slatopolsky E
    J Clin Endocrinol Metab; 1991 Apr; 72(4):735-9. PubMed ID: 2005198
    [No Abstract]   [Full Text] [Related]  

  • 19. Dialysis bone disease.
    Ritz E; Krempien B; Kuhn H; Heuck F
    Isr J Med Sci; 1971 Mar; 7(3):520. PubMed ID: 5567544
    [No Abstract]   [Full Text] [Related]  

  • 20. Toxicity of parathyroid hormone in uremia.
    Klahr S; Slatopolsky E
    Annu Rev Med; 1986; 37():71-8. PubMed ID: 3010810
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.